IN THE SPOTLIGHT

Treatment of Advanced Stage NSCLC Without Targetable Biomarkers - Recorded Video

Treatment of Advanced Stage NSCLC Without Targetable Biomarkers - Recorded Video

In this webinar, we discuss treatment of metastatic NSCLC that does not have targetable biomarkers.Hear from guest speakers Denise Cutlip (patient advocate) and Dr. Benjamin Levy (Thoracic Oncologist & Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital).  Dr. Levy is a physician-scientist who runs clinical trials in lung cancer. He is a member of LUNGevity's Scientific Advisory Board.This webinar was originally recorded as a…

Building a Computational Model to Optimize Patient Treatment

Building a Computational Model to Optimize Patient Treatment

Approximately 20%-35% of patients newly diagnosed with non-small cell lung cancer (NSCLC) will have locally advanced disease, sometimes referred to as stage III NSCLC. The definitions of locally advanced disease can be complex. Generally, in these cases, the tumor may have grown into other areas close to the lung, such as the diaphragm or esophagus, or spread to nearby lymph nodes. However, the disease would not have spread to distant parts of the body. The standard treatments of locally…

LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards

LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards

LUNGevity Foundation is proud to announce the recipients of four awards to bolster the lung cancer research workforce— the Career Development Award, the VA Research Scholar Award, the Health Equity and Inclusiveness Research Fellow Award, and the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant.“Progress in lung cancer research is only possible with a vibrant and diverse thoracic oncology workforce,” notes Upal Basu Roy, PhD, MPH, executive director, LUNGevity Research. “We…

Treatment & Research Takeaways: ESMO 2023 Meeting

Treatment & Research Takeaways: ESMO 2023 Meeting

The European Society for Medical Oncology (ESMO) recently held its annual conference from October 20 – 24, 2023 in Madrid, Spain. ESMO represents one of the largest gatherings of the international oncology community, and this year’s meeting had over 30,000 registered attendees from around the world.  Though October 19th brought record rainfall to Madrid, breaking a 100-year record, the rain in Spain didn’t dampen the palpable excitement of this year’s meeting. This was an especially…

What Is a Clinical Trial

What Is a Clinical Trial

Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung cancer research and access to new treatments that otherwise may not be available to them, all under the close supervision of medical experts. 

Watch Recorded Expert Sessions From ILCSC

Watch Recorded Expert Sessions From ILCSC

The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference was held September 22-23.  The recorded sessions from this conference are available to registered participants through December 21, 2023, at www.lungevity.org/ilcsc. If you did not register for the conference but would like to view the recordings, you may still register for free access. The recordings are…

The Latest Lung Cancer Science: Highlights of WCLC 2023

The Latest Lung Cancer Science: Highlights of WCLC 2023

I had the privilege of attending the 2023 World Conference on Lung Cancer (WCLC) in Singapore with my colleague Dr. Bellinda King-Kallimanis. WCLC, the world's largest meeting dedicated to lung cancer and other thoracic malignancies, is an excellent forum for learning about the latest research into the early detection and treatment of lung cancer. Apart from the science, it was inspiring to see fellow advocates and network with brilliant researchers, all razor-focused on improving the outcomes…

Decentralized Trials: Bringing Clinical Trials Closer to the Patient

Decentralized Trials: Bringing Clinical Trials Closer to the Patient

While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. The U.S. Food and Drug…

2023 ASCO: Highlights of Lung Cancer Research

2023 ASCO: Highlights of Lung Cancer Research

Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical representatives, advocates, and patients, to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 2 through June 6, 2023. The theme for this year’s conference, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” was in recognition of…

Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer

Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer

As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx seeks to understand lung cancer at its most basic level, “tracing” the clues that may predict how it starts and eventually changes over time so that doctors can treat it better.Collecting comprehensive genomic and clinical data from over 800 people with non-small cell lung cancer (NSCLC), Dr. Swanton and a team of…

The Basics of Neuroendocrine Tumors (NETs)

The Basics of Neuroendocrine Tumors (NETs)

Our lung tissue is made of different kinds of cells, including neuroendocrine cells. If these cells develop changes in their genome, they can begin to grow out of control and become tumors. Large cell lung cancer (which is the rarest form of non-small cell lung cancer) and small cell lung cancer (also referred to as SCLC) are both neuroendocrine tumors (NETs), derived from neuroendocrine cells in the lungs. LUNGevity spoke with Lauren Byers, MD, professor in the Department of Thoracic/Head…

Tackling the Biggest Challenges in Cancer

Tackling the Biggest Challenges in Cancer

Cancer Grand Challenges is a partnership between Cancer Research UK (CRUK) and the National Cancer Institute (NCI), which funds global teams of leading researchers across various scientific disciplines to tackle some of the toughest challenges in cancer research. As Dinah Singer, Acting Director of NCI’s Center for Strategic Scientific Initiatives says, “Cancer research is a global endeavor.” As LUNGevity’s Vice President of Global Engagement and Patient Partnerships, I recently attended…

Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting

Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting

The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies. During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients. Each year, there is one key conference…

An Introduction to Squamous Cell Lung Cancer

An Introduction to Squamous Cell Lung Cancer

Lung squamous cell carcinoma (LSCC), also called squamous cell lung cancer, is one of the major subtypes of non-small cell lung cancer (NSCLC). Fifty years ago, LSCC was the most common lung cancer diagnosis. LSCC was considered the classic smoker’s lung cancer, as most patients with LSCC had a history of smoking cigarettes. Today, the incidence of LSCC depends on where you live. In areas with decreasing smoking rates, we’ve also seen a reduction in the number of LSCC diagnoses. Overall, while…

Science Spotlight: NSCLC Transformation into SCLC

Science Spotlight: NSCLC Transformation into SCLC

Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Triparna Sen, PhD, as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC, including EGFR, ALK, and RET. This Facebook Live event is hosted by Amy Moore, PhD, LUNGevity’s Vice President of Global Engagements and Patient Partnerships. Dr. Sen is Co-…

Key Findings from ASCO 2022

Key Findings from ASCO 2022

Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, speaks with Charles Rudin, MD, PhD, about the key findings from the recent meeting of the American Society for Clinical Oncology (ASCO) and what they mean for the lung cancer community.

We're Live-Tweeting from ASCO June 3-7!

We're Live-Tweeting from ASCO June 3-7!

LUNGevity’s Dr. Upal Basu Roy and Dr. Amy Moore will be live-tweeting from the American Society of Clinical Oncology (ASCO) annual meeting. Follow LUNGevity on Twitter and the hashtags #ASCO22 and #LCSM to be a part of the action. Times and topics of live-tweeted sessions are as follows: Fri, Jun 3, 2022 | 2:00 PM – 5:00 PM EDT | Lung Cancer—Non-Small Cell Metastatic  Sun, Jun 5, 2022 | 9:00 AM – 10:15 AM EDT | Treatment Sequencing in Resectable Lung Cancer…

Lung Cancer Treatment Landscape: New Options and Ongoing Challenges

Lung Cancer Treatment Landscape: New Options and Ongoing Challenges

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.

Discovering a New Approach to Treat Metastatic NSCLC

Discovering a New Approach to Treat Metastatic NSCLC

Lung cancer continues to be the number-one cause of cancer deaths in the United States. In the past decade, we have seen great improvements in the treatment of metastatic lung cancer with targeted therapies and immunotherapy. “When targeted therapies aren’t an option, the current standard of care for patients is immunotherapy alone or in combination with chemotherapy. But many patients don’t respond to these treatments the way we’d like them to,” said Sean Pitroda, MD, assistant professor of…

New Options in Adjuvant Therapy for Early-Stage NSCLC

New Options in Adjuvant Therapy for Early-Stage NSCLC

Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of…

Highlights of the 2022 AACR meeting

Highlights of the 2022 AACR meeting

The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in person to make this year’s meeting one of the largest gatherings since the start of the pandemic. They shared the many exciting developments in cancer research and treatment that emerged over the last year. This year’s meeting is another testament to “Science doesn’t stop, and scientists never sleep!” Here, we discuss…